• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • Articles
    • News
    • Events
    • Resources
    • M&C Reacts
  • Contact Us
Marks & Clerk logo
Marks & Clerk logo
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • Articles
  • News
  • Events
  • Resources
  • M&C Reacts

Neurim v Mylan: Take Two

Header image: Laboratory with microscope and test tubes
10 August 2021
Ian Turner
Print
Share

Last time we were writing about the Neurim v Mylan battle concerning Circadin (“Going out with a Bang, what a difference 2 days makes”) it was Mylan with the upper hand ([2021] EWHC 530 (Pat)).  Neurim had been successful in the UK trial ([2020] EWHC 3270 (Pat)) but then lost that patent at the EPO by withdrawing their appeal (following negative indications at the oral proceedings).  Fast-forward to a busy last week of court term and Mr Justice Mellor (in a judgment dated 2 August 2021) has given Neurim a fighting chance of obtaining an injunction against Mylan by agreeing that Neurim can have an expedited preliminary issue trial ([2021] EWHC 2198 (Pat)).

This situation has arisen because a divisional patent (EP 3 103 443) granted on 30 June 2021 (but expires 12 August 2022).  Neurim promptly sued Mylan on the new divisional and are asserting that, because they were successful at the prior UK trial, Mylan are estopped from asserting invalidity or non-infringement. The normal course of UK litigation, while quick, would not provide Neurim with a judgment until after the patent has expired.  Further, an interim injunction is not a course realistically open to Neurim (this question between the parties has already been to the UK Court of Appeal: [2020] EWCA Civ 793)).

Mylan says the case is not so straightforward and has, in any event, applied to stay the action pending its opposition at the EPO (that application for a stay is to be heard in October 2021).

The issues ventilated at the hearing of the application are relatively complex (inevitably given the convoluted history of this dispute).  Mylan correctly argued that the circumstances do not present a set of preliminary issues which will necessarily be decisive because they are not purely questions of law.  However, ultimately, Mr Justice Mellor sided with Neurim and ruled “that it is just and right that Neurim should be afforded the opportunity to establish its patent right by way of a trial of preliminary issues – this being the only realistic way in which Neurim can hope to secure injunctive relief before expiry of EP443”. 

Further, expedition was permitted even though Mylan are unlikely to be able to use their chosen lead counsel and over the summer costs might be wasted by preparing for a trial which is ultimately stayed (if Mylan is successful on their application for a stay pending a decision by the EPO).

The October stay application will be the next instalment and after that a trial of preliminary issues is scheduled to be heard before the end of February 2022.  It will be interesting to see how Take Two progresses particularly as Mylan’s main defence is essentially about abuse of the patent system and so may be strategically instructive to patentees and challengers alike.

Next Story
  • Going out with a Bang, what a difference 2 days makes: Neurim v Mylan
More insights

Latest Insights

News
- 10 August 2022

Marks & Clerk’s trade mark team also celebrates exam success!

In addition to our excellent patent team results in July, we are also thrilled to announce that several members of the Marks & Clerk Trade Mark team are enjoying exam success.
Read more
Blockchain/cryptocurrency concept: 3D cubes
Article
- 05 August 2022

Patenting DLT innovations in Europe

In Europe, inventions that utilise distributed ledger technology will generally fall under the heading of “computer-implemented inventions (CIIs).”
Read more
Blockchain concept: blue chains with code in the background
Article
- 05 August 2022

Applications of DLTs

The immutable nature of the data stored in a DLT leads to a host of applications across different sectors. The best known application is that of cryptocurrencies, such as Bitcoin.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Lexology
  • Mondaq